Jinqin Q. Liu

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Genomic landscape, clinical correlates and prognostic implications of U2AF1 mutation subtypes in myelodysplastic neoplasms.

Genomic landscape, clinical correlates and prognostic implications of U2AF1 mutation subtypes in myelodysplastic neoplasms.

Journal: Blood cancer journal

Published: April 23, 2026

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.

Journal: Blood cancer journal

Published: February 12, 2026

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms.

Journal: Blood

Published: March 04, 2025

Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1S34F mutant myelodysplastic neoplasms.

Aberrant splicing of CHEK1 is a driver of megakaryocytic dysplasia in U2AF1S34F mutant myelodysplastic neoplasms.

Journal: Leukemia

Published: December 02, 2024

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms.

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms.

Journal: Experimental hematology & oncology

Published: November 27, 2024

GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms.

GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms.

Journal: Pathology, research and practice

Published: September 02, 2024

Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement.

Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement.

Journal: Leukemia & lymphoma

Published: June 24, 2023

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins.

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins.

Journal: Blood science (Baltimore, Md.)

Published: April 16, 2023

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.

Journal: Blood cancer journal

Published: January 31, 2023

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy.

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy.

Journal: Leukemia research reports

Published: January 17, 2023

Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates.

Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates.

Journal: Hematological oncology

Published: October 20, 2022

Recent progress in the diagnosis and treatment of cold agglutinin disease

Recent progress in the diagnosis and treatment of cold agglutinin disease

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: August 15, 2022

Showing 1-12 of 38

Last Updated: 09/26/2026